Phase III Study of ASP7374 Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
Price : $35 *
At a glance
- Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 10 Jan 2017 According to an Astellas Pharma media release, the company will withdraw the application for marketing approval of ASP7374 which the company has filled in Japan as the company has terminated the development agreement with UMN Pharma.
- 11 Mar 2013 Results have been reported in an Astellas Pharma media release.
- 18 Jan 2013 New source identified and integrated (ClinicalTrials.gov record NCT01767896).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History